Securitas

Good Q1 2025, portfolio review

08/05/25 -"Organic sales growth and operating margin improvement were in line with expectations, with all divisions contributing to the overall performance. At constant currency, sales growth in Technology and ..."

PDF page sample
Pages
47
Language
English
Published on
08/05/25
Download
You may also be interested by these reports :
23/10/26
SGS’ Q3 revenues were modestly above expectations, led by a solid contribution from scope and stable organic growth. The beat, however, was largely ...
22/10/26
Rentokil Initial’s Q3’26 organic revenue growth of 3.4% was in line with expectations, with FY26 profit guidance reiterated. Improving contract ...
21/10/26
Eurofins Scientific posted a slight beat on organic growth and revenues, supported by continued strong growth in C&T Product Testing and an ...
21/10/26
Organic revenue growth accelerated beyond expectations in Q3 2026, broadening across geographies. However, the gross margin pressure persisted due to ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO